Literature DB >> 12928057

Immune responses against Abeta1-42 in HLA class II transgenic mice: implications for Abeta1-42 immune-mediated therapies.

Pritam Das1, Svetlana Chapoval, Victor Howard, Chella S David, Todd E Golde.   

Abstract

We have investigated whether polymorphic differences in the major histocompatibility complex (MHC) class II molecules influence humoral and cellular immune responses against Abeta1-42. To analyze the effects of mouse MHC class II and tolerance effects of overexpression of human APP in mice, we immunized Tg2576 and non-transgenic littermates bred into two different MHC backgrounds with Abeta1-42 and compared both B and T cell responses. We found that in the presence of the mouse C57BL/6 background, both B and T cell responses against Abeta1-42 were significantly suppressed. To directly test the contribution of human MHC class II, we immunized various human HLA class II transgenic (TG) mice with Abeta1-42 and analyzed anti-Abeta immune responses. HLA-DR3 and HLA-DQ8 TG mice generated modest B and T cell responses against Abeta1-42. The presence of HLA-DR3/DQ8 in double TG mice enhanced the overall immune response against Abeta1-42. In contrast, HLA-DR4 TG mice mounted strong T cell responses but failed to generate high titer antibody responses against Abeta1-42, whereas, the HLA-DQ6 TG mice were not able to mount significant B or T cell responses against Abeta1-42. These studies in mice suggest that the presence of certain MHC class II molecules or combinations of class II molecules can potentially influence the overall immune response against Abeta1-42.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 12928057     DOI: 10.1016/s0197-4580(03)00036-8

Source DB:  PubMed          Journal:  Neurobiol Aging        ISSN: 0197-4580            Impact factor:   4.673


  15 in total

Review 1.  Alzheimer's therapeutics: translation of preclinical science to clinical drug development.

Authors:  Alena V Savonenko; Tatiana Melnikova; Andrew Hiatt; Tong Li; Paul F Worley; Juan C Troncoso; Phil C Wong; Don L Price
Journal:  Neuropsychopharmacology       Date:  2011-09-21       Impact factor: 7.853

2.  Abeta-induced meningoencephalitis is IFN-gamma-dependent and is associated with T cell-dependent clearance of Abeta in a mouse model of Alzheimer's disease.

Authors:  Alon Monsonego; Jaime Imitola; Sanja Petrovic; Victor Zota; Anna Nemirovsky; Rona Baron; Yair Fisher; Trevor Owens; Howard L Weiner
Journal:  Proc Natl Acad Sci U S A       Date:  2006-03-20       Impact factor: 11.205

3.  Intradermal active full-length DNA Aβ42 immunization via electroporation leads to high anti-Aβ antibody levels in wild-type mice.

Authors:  Roger N Rosenberg; Min Fu; Doris Lambracht-Washington
Journal:  J Neuroimmunol       Date:  2018-06-11       Impact factor: 3.478

4.  The second-generation active Aβ immunotherapy CAD106 reduces amyloid accumulation in APP transgenic mice while minimizing potential side effects.

Authors:  Christoph Wiessner; Karl-Heinz Wiederhold; Alain C Tissot; Peter Frey; Simone Danner; Laura H Jacobson; Gary T Jennings; Rainer Lüönd; Rainer Ortmann; Julia Reichwald; Mauro Zurini; Anis Mir; Martin F Bachmann; Matthias Staufenbiel
Journal:  J Neurosci       Date:  2011-06-22       Impact factor: 6.167

5.  Amyloid-beta vaccination, but not nitro-nonsteroidal anti-inflammatory drug treatment, increases vascular amyloid and microhemorrhage while both reduce parenchymal amyloid.

Authors:  D M Wilcock; P T Jantzen; Q Li; D Morgan; M N Gordon
Journal:  Neuroscience       Date:  2006-11-28       Impact factor: 3.590

6.  Abeta-immunotherapy for Alzheimer's disease using mannan-amyloid-Beta peptide immunoconjugates.

Authors:  Anahit Ghochikyan; Irina Petrushina; Andrew Lees; Vitaly Vasilevko; Nina Movsesyan; Adrine Karapetyan; Michael G Agadjanyan; David H Cribbs
Journal:  DNA Cell Biol       Date:  2006-10       Impact factor: 3.311

Review 7.  CD4 T cells in immunity and immunotherapy of Alzheimer's disease.

Authors:  Alon Monsonego; Anna Nemirovsky; Idan Harpaz
Journal:  Immunology       Date:  2013-08       Impact factor: 7.397

Review 8.  Rationale for peptide and DNA based epitope vaccines for Alzheimer's disease immunotherapy.

Authors:  Anahit Ghochikyan
Journal:  CNS Neurol Disord Drug Targets       Date:  2009-04       Impact factor: 4.388

9.  DNA prime-protein boost increased the titer, avidity and persistence of anti-Abeta antibodies in wild-type mice.

Authors:  H Davtyan; M Mkrtichyan; N Movsesyan; I Petrushina; G Mamikonyan; D H Cribbs; M G Agadjanyan; A Ghochikyan
Journal:  Gene Ther       Date:  2009-10-29       Impact factor: 5.250

Review 10.  Treatment strategies targeting amyloid β-protein.

Authors:  Dale Schenk; Guriqbal S Basi; Menelas N Pangalos
Journal:  Cold Spring Harb Perspect Med       Date:  2012-09-01       Impact factor: 6.915

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.